Home › Early Findings with KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting
 

Keywords :   


Early Findings with KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting

2015-04-19 18:45:00| Merck.com - Product News

Dateline City: PHILADELPHIA KEYTRUDA Demonstrated 28 Percent Overall Response Rate and 76 Percent Disease Control Rate in Difficult-to-Treat Cancer First Findings from KEYNOTE-028, Mercks Innovative Basket Trial in 20 Cancers PHILADELPHIA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in 25 patients with advanced pleural mesothelioma, a difficult-to-treat cancer of the lining of the lungs, abdomen and other organs. The early findings presented showed an overall response rate (confirmed and unconfirmed) of 28 percent with KEYTRUDA in patients with tumors that expressed PD-L1. Language: English Contact: Media:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: advanced early presented meeting

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
11.10Tropical Storm Leslie Graphics
11.10Tropical Storm Leslie Forecast Discussion Number 36
11.10Tropical Storm Leslie Wind Speed Probabilities Number 36
11.10Tropical Storm Leslie Public Advisory Number 36
11.10Summary for Tropical Storm Leslie (AT3/AL132024)
11.10Tropical Storm Leslie Forecast Advisory Number 36
11.10China detains iPhone maker workers in 'strange' case
11.10UK economy returned to growth in August
More »